A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people with newly diagnosed multiple myeloma who are ineligible for stem cell transplants, compared with Revlimid and dexamethasone alone, results from a Phase 3…
Allogene Therapeutics and SpringWorks Therapeutics have launched a clinical trial collaboration to conduct a Phase 1 study assessing an ALLO-715 combination therapy in people with relapsed or refractory multiple myeloma. The trial will test…
Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple myeloma — a precursor of multiple myeloma — is safe and may halt the disease’s progression into the full-blown condition, a Phase 2 trial shows.
Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion of an anticipated Phase 1/2 trial. The companies plan to file an investigational new drug application for HPN217 with the U.S. Food and Drug Administration…
A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe and highly effective for the treatment of newly diagnosed multiple myeloma, results of a Phase 2 clinical trial show. The study, “Phase 2 Study…
Real world data from multiple myeloma patients in Hungary supports the use of a triple combination regimen — Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone — in people already heavily treated for this disease. The study, “Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination…
Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “Maintenance Treatment and Survival in Patients With Myeloma,” was published in the journal JAMA Oncology. The continuous therapy approach, which consists of administering a…
Older multiple myeloma patients who are unable to receive a stem cell transplant could receive Ninlaro (ixazomib) as part of their first line-therapy instead of standard Velcade (bortezomib), according to the results of a clinical trial. While Ninlaro- and Velcade-based therapies showed similar response rates, oral dosing and…
A new Phase 3 clinical trial called ACCoRd is underway to investigate the benefits of adding Ninlaro (ixazomib) – a proteasome inhibitor – to the conditioning regimen prior to a second stem cell transplant in patients with relapsed multiple myeloma. The protocol for ACCoRd is outlined in an article,…
In an era of new therapies with unprecedented efficacy, high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) is still associated with better progression-free survival in newly-diagnosed multiple myeloma patients, researchers found. Autologous transplants use the patient’s own stem cells. A meta-analysis of randomized Phase 3 trials, titled…
Get regular updates to your inbox.